| EPSRC Reference: |
EP/V034723/1 |
| Title: |
CMMI-EPSRC - Right First Time Manufacture of Pharmaceuticals (RiFTMaP) |
| Principal Investigator: |
Cordiner, Professor J |
| Other Investigators: |
|
| Researcher Co-Investigators: |
|
| Project Partners: |
|
| Department: |
Chemical & Biological Engineering |
| Organisation: |
University of Sheffield |
| Scheme: |
Standard Research |
| Starts: |
01 September 2021 |
Ends: |
31 August 2025 |
Value (£): |
1,543,633
|
| EPSRC Research Topic Classifications: |
| Control Engineering |
Design Engineering |
| Design of Process systems |
Manufact. Enterprise Ops& Mgmt |
| Particle Technology |
|
|
| EPSRC Industrial Sector Classifications: |
| Manufacturing |
Healthcare |
| Pharmaceuticals and Biotechnology |
Information Technologies |
|
| Related Grants: |
|
| Panel History: |
|
|
Summary on Grant Application Form |
The UK pharmaceutical industry produces 16% of the world's well-known medicines, employs more than 66,000 people (200,000 more indirectly) and contributes over £8.8 billion to the UK GVA. The current covid-19 crisis has highlighted the need for the UK and the USA to have a strong, smart pharmaceutical manufacturing base. The FDA in the USA has identified continuous pharmaceutical manufacturing as a highly promising solution to these challenges by enabling lower capital cost, smaller footprint and highly efficient facilities, which can be distributed geographically, improve national security by reducing dependency on foreign suppliers and can produce multiple products on demand with minimum risk to quality. However, the UK Government Made Smarter Review highlights that we still have a way to go to achieve a Right First Time smart manufacturing system as an enabler for the digitalization of continuous manufacturing in pharmaceutical industry.
Addressing these challenges are the domain of process systems engineers. By developing right-first-time (RFT) smart manufacturing systems incorporating Industry 4.0 concepts, we intend to address these key challenges in pharmaceutical manufacturing. Our hypothesis is that the development of a systematic framework for smart continuous pharmaceutical manufacturing can deliver key benefits to the industry including:
- Reduced time to market of new products;
- Reduced waste and increased resilience; and
- Reduced cost of manufacture.
To develop this framework, we have brought together a world leading team of process systems and pharmaceutical engineers from four universities in the UK and USA. An important and unique element of this proposal is the ability to validate state of the art models, control and optimization procedures on three cutting edge continuous manufacturing experimental platforms: (1) Consigma 25 wet granulation line at University of Sheffield (UK); (2) Dry granulation line at Purdue University (USA); and (3) Continuous direct compression line, also at Purdue.
The outcome of this project will be a framework and computational tools for optimal design of pharmaceutical processes with a real-time process management system and a flexible real-time release testing framework, all verified at pilot scale.
|
|
Key Findings |
|
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
|
|
Potential use in non-academic contexts |
|
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
|
|
Impacts |
|
| Description |
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk |
| Summary |
|
| Date Materialised |
|
|
|
|
Sectors submitted by the Researcher |
|
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
|
| Project URL: |
|
| Further Information: |
|
| Organisation Website: |
http://www.shef.ac.uk |